The FDA's Decision to Reverse Course on Lequembe

Eli Lilly said they plan to file with the FDA this quarter, so by the end of June. And Dave Rinks said on CNBC, Dave Ricks being the CEO of Eli Lilly, that they're hoping for approval by theend of the year. But even before that happens, the full approval, Padufa date, FDA decision date for Lequembe is July 6. So when that happens, I think all eyes will be on the Centers for Medicare and Medicaid services as to does that trigger them to change their very limited coverage decision for amyloid targeted Alzheimer's drugs to more broadly cover them.